Crescent Biopharma, Inc. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/880729f1-4cfe-4ef6-ae9f-6ff80f3a53ae/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-152.6M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-011983 |
| FY 2024 | $-40.0M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-000948 |
| FY 2023 | $-39.3M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-004013 |
| FY 2022 | $-47.4M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-004864 |
| FY 2021 | $-63.4M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002737 |
| FY 2020 | $-51.5M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002222 |
| FY 2019 | $-61.4M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001723 |
| FY 2018 | $-51.5M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001537 |
| FY 2017 | $-33.9M | 2017-01-01 – 2017-12-31 | evidence 0001558370-18-001553 |
| FY 2016 | $-31.9M | 2016-01-01 – 2016-12-31 | evidence 0001558370-17-001198 |
| FY 2015 | $-12.8M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-003688 |
| FY 2014 | $-11.1M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-093802 |
| FY 2013 | $-68.3M | 2003-05-21 – 2014-03-31 | evidence 0001193125-14-192508 |
| FY 2012 | $3.6M | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-093802 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).